(iii) conversion of the resulting compound of formula (I) into a salt or solvate thereof.

28. The process for preparation of compound of formula (III), or pharmaceutically acceptable salt, solvate or prodrug thereof as defined in claim 15, wherein process comprises following steps:

(a-1) process steps from (a) to (m) for preparation of compound of formula (I) followed by:

(b-1) reacting a compound of formula (I) obtained in step (a-1) with a compound of formula X^{1m}-W^{m}-X^{2m}, wherein X^{1m} and X^{2m} are the appropriate reactive or leaving groups or groups convertable to X^{1} and X^{2} as defined above for formula (III), and W^{m} is W or the appropriate precursor convertable to W wherein W is as defined for formula (III) above;

(c-1) cyclizing compound obtained in step (b-1) and thereafter, if required after any of steps (a-1) to (c-1), subjecting the resulting compound to one or more of the following operations:

(i) removal of the protecting group R^{p},

(ii) conversion of X^{1m}, X^{2m} and W^{m} to X^{1}, X^{2} and W,

(iii) removal of S^{2} sugar group and/or S^{1} sugar group,

(iv) conversion of the resulting compound of formula (III) into a pharmaceutically acceptable salt, solvate, or prodrug thereof.

29. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to claim 15.

30. The pharmaceutical composition according to claim 29 comprising a further therapeutic agent.

31. The compound according to claim 15 or the pharmaceutical composition according any one of claims 29-30 for use in medicine.

32. A compound according to claim 15 or the pharmaceutical composition according any one of claims 29-30, for use in the prophylaxis and/or treatment of diseases or conditions selected from conditions involving inflammation or immune responses, and/or autoimmune diseases.

33. The compound or pharmaceutical composition for use according to claim 32, wherein said compound or pharmaceutical composition is to be administered in combination with a further therapeutic agent.

34. Use of the compound according to claim 15, or the pharmaceutical composition according any one of claims 29-30 in the manufacture of a medicament for the prophylaxis

and/or treatment of diseases or conditions selected from conditions involving inflammation or immune responses, and/or autoimmune diseases.

35. The use according to claim 34, wherein the compound or the pharmaceutical composition is to be administered in combination with a further therapeutic agent.